Search | Clinical Trials Finder

Conditions: Neoplasms, Breast
Interventions: Lapatinib/nab-Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 13
States / cities: La Verne, California • Long Beach, California • Fort Myers, Florida + 10 more

Conditions: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Interventions: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging); Drug
Lead sponsor: Aktis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Duarte, California • Irvine, California • Miami, Florida + 10 more

Conditions: Breast Cancer, Prostate Cancer
Interventions: ferumoxytol, magnetic resonance imaging; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Cancer
Interventions: Venetoclax, Capecitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 11
States / cities: Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more

Conditions: Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
Interventions: SHY-ONC6; Drug
Lead sponsor: SHY Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Scottsdale, Arizona • Denver, Colorado • Houston, Texas + 1 more

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon

Conditions: Breast Cancer
Interventions: ARV-471, Ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Palo Alto, California • San Francisco, California • Tampa, Florida + 7 more

Conditions: Cancer of the Breast, Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Male Breast Cancer, Triple Negative Breast Cancer, ER+ Breast Cancer
Interventions: Seviteronel; Drug
Lead sponsor: Innocrin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Aurora, Colorado + 30 more

Conditions: Locally Advanced or Metastatic Breast Cancer
Interventions: Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Breast Cancer
Interventions: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane), Sorafenib (Nexavar); Drug
Lead sponsor: Veeda Oncology; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Triple Negative Breast Cancer
Interventions: TheraBionic P1; Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 22 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: Evexomostat; Drug
Lead sponsor: SynDevRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Loma Linda, California • Newport, California • San Diego, California + 7 more

Conditions: Breast Cancer
Interventions: None (Observational Study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 40
States / cities: Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more

Conditions: HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations, Somatic BRCA1/2 Mutations
Interventions: Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Towson, Maryland • Jackson, Mississippi

Conditions: Breast Cancer
Interventions: Fulvestrant, MLN9708; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: anastrozole, gefitinib, fulvestrant, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions: GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)]); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer
Interventions: CX-2009; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more

Conditions: Breast Neoplasm
Interventions: Sagopilone (ZK 219477); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 21
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 18 more

Conditions: Breast Cancer
Interventions: Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 23
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more

Conditions: Breast Neoplasms
Interventions: Enzastaurin Hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Newark, Delaware • Indianapolis, Indiana • South Bend, Indiana + 1 more

Conditions: Breast Cancer
Interventions: Tarceva; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Y-90 SIR-Spheres, Yttrium-90 Microsphere Radioembolization, Systemic Therapy; Device · Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Phase I Study of the Combination of MLN9708 and Fulvestrant

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy